葡萄糖氯己定(Chlorhexidine gluconate) - 在研适应症：感染，细菌性皮肤疾病，牙龈疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Chlorhexidine gluconate (JP17/USP)、Chlorhexidine Gluconate Solution、グルコン酸クロルヘキシジン

+ [38]

靶点-

作用方式

抑制剂

作用机制

细胞膜功能抑制剂

治疗领域

感染口颌疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

感染细菌性皮肤疾病牙龈疾病+ [4]

非在研适应症

慢性牙周炎种植体周围炎牙周炎+ [1]

原研机构

Sumitomo Pharma Co., Ltd.

在研机构

Maruishi Pharmaceutical Co., Ltd.Bridgewest Perth Pharma Pty Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

+ [9]

非在研机构

Dexcel Pharma Technologies Ltd.

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1959-09-22),

消毒剂

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C34H54Cl2N10O14

InChIKeyYZIYKJHYYHPJIB-UUPCJSQJSA-N

CAS号18472-51-0

关联

541

项与葡萄糖氯己定相关的临床试验

NCT06967402

/ Not yet recruitingN/A

Comparative Clinical Efficacy and Microbiological Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Severe Periodontitis

The focus of this study is on two types of mouthwashes - one containing a chlorhexidine (CHX) at 0.2% (CHX), and the other one containing CHX at a lower concentration of 0.12% with cetylpyridinium chloride (CPC). Both mouthwashes are used to help in the treatment of gum disease. CHX has been known for a long time for its effectiveness against plaque and mouth inflammation. It could inhibit and even kill them. However higher concentrations of CHX comes with unwanted side effect including altered taste, teeth staining and irritation in the mouth. Interestingly, these side effects seem to occur less frequently when a lower concentration CHX solution is used. CPC also combats bacteria by adhering quickly to the surfaces inside your mouth, although it has less substantivity than CHX, it has been shown to reduce plaque and gum inflammation effectively, and it typically causes fewer side effects than CHX. We hypothesize that this new formulation of CHX 0.12%+CPC mouthwash is non-inferior to CHX 0.2% in terms of its anti-plaque and anti-inflammatory properties while presenting with less side effects after 21 days of use. Microbiological samples and fluids from periodontal pockets will be collected before and after treatment for analysis of microbiological effects.

开始日期2025-07-01

申办/合作机构

香港大学

[+1]

CTRI/2025/04/085327

/ Not yet recruiting临床4期IIT

One-year Comparative evaluation of effect of emblica officinalis, Epigallactocatechin-3-gallate, chlorhexidine using selective etch technique on clinical performance of composite resin restoration in cases of Non carious cervical lesions: A randomized clinical study - NIL

开始日期2025-05-15

申办/合作机构-

CTRI/2025/04/085249

/ Not yet recruiting临床3期IIT

Efficacy of Sodium Hypochlorite, Chitosan and Chlorhexidine Gluconate as non-activated and Endo-Activator activated irrigants on Microbial Load, Obturation Quality and Post-Endodontic Pain In Primary Teeth- A Randomized Comparative Clinical Study - NIL

开始日期2025-05-06

申办/合作机构-

100 项与葡萄糖氯己定相关的临床结果

登录后查看更多信息

100 项与葡萄糖氯己定相关的转化医学

登录后查看更多信息

100 项与葡萄糖氯己定相关的专利（医药）

登录后查看更多信息

8,559

项与葡萄糖氯己定相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Evaluation of the effects of Andiz extract on the experimentally wound in rats by microbiological and gene expression methods

Article

作者: Kavut, Büşra Sümeyye ; Önalan, Şükrü ; Talmaç, Ahmet Cemil

OBJECTIVES:

This study aimed to investigate the effects of andiz extract on wound healing and compare it with saline and chlorhexidine gluconate. Microbial DNA load was used to evaluate its antibacterial effects, and gene expression methods were used to assess its contribution to cytokine release and wound healing.

METHODS AND RESULTS:

A standardized wound site was created with a 3 mm diameter punch on 32 male Wistar albino rats. The rats were divided into four groups: Control (n = 5), Saline (n = 9), Chlorhexidine gluconate (n = 9), and Andiz extract (n = 9). Five rats in the control group were euthanised without any treatment. Irrigations of the Saline, Chlorhexidine, and Extract groups were provided regularly. After the tissue samples were taken in the 1st week, 2nd week, and 3rd week, three rats were euthanized each week for each group. The total bacterial DNA load on the samples taken was determined by a nano spectrophotometer. β-actin was chosen as housekeeping, and target gene primers were created for TGF-β and IL-1β. Expression amounts of target genes were measured by Real-Time PCR with the application of the created primers. There is a significant difference between the Extract group and the other groups regarding total bacterial DNA load. The whole bacterial load was 185% less than the initial values. TGF-β and IL-1β genes evaluated regarding gene expression were measured at the highest value in the Extract group.

CONCLUSIONS:

This study showed the antibacterial effects of the Extract and its positive contributions to wound healing.

2025-09-01·COLLOIDS AND SURFACES B-BIOINTERFACES

Impact of different chemical debridement agents on early cellular responses to titanium dental implants: A transcriptome-based in vitro study on peri-implant tissue regeneration

Article

作者: Sigurjónsson, Ólafur Eysteinn ; Wang, Qiang ; Linke, Dirk ; Haugen, Håvard Jostein ; Ma, Qianli ; Lyngstadaas, Ståle Petter

BACKGROUND:

Poor peri-implant health leads to biofilm accumulation, peri-implantitis, and bone loss. Chemical debridement may help maintain peri-implant health, but its effects on peri-implant cells remain unclear.

METHODS:

Five cleaning agents-hydrogen peroxide (H2O2), Poloxamer, H2O2 +Poloxamer, Perisolv, and Paroex-were applied on titanium (Ti) surfaces. Mouse pre-osteoblasts (MC3T3-E1), human gingival fibroblasts (HGF), and human bone marrow stromal cells (hBMSC) were cultured on agent-treated Ti surfaces for up to 120 minutes to assess morphology, cytotoxicity, adhesion, and proliferation. RNA sequencing was performed on hBMSC.

RESULTS:

Except for Poloxamer, all treatments inhibited cellular spreading. Paroex increased cytotoxicity and inhibited proliferation. Perisolv impaired hBMSC adhesion and variably affected proliferation. H2O2, alone or with Poloxamer, elevated cytotoxicity and inhibited adhesion in hBMSCs but not MC3T3-E1 or HGF. In contrast, Poloxamer-treated Ti surfaces enhanced adhesion and proliferation across all cell types. RNA sequencing revealed that oxidant-based treatments (H2O2, H2O2 +Poloxamer, Perisolv) suppressed key genes for proliferation (HMGA2, JAG1, NOTCH1, YAP1, TBX3), anti-apoptosis (MCL1, BCL2L2), and adhesion (ITGA2, ITGB3, SPP1), while inhibiting MAPK, PI3K-Akt, and pluripotency pathways.

CONCLUSION:

Commercial agents like Perisolv and Paroex impair hBMSC function, with Paroex demonstrating significant cytotoxicity. H2O2 exhibits toxicity, particularly to hBMSCs. Poloxamer improves cell attachment and growth. Given these findings, careful selection of debridement agents is critical to balance cleaning efficacy and cytocompatibility. The adverse effects on hBMSCs necessitate prompt removal postapplication. Further research on biomaterials supporting tissue regeneration postdebridement is needed to restore peri-implant health.

2025-08-01·Complementary Therapies in Clinical Practice

Effects of Zataria multiflora mouthwash and chlorhexidine compared to chlorhexidine alone on the incidence of ventilator-associated pneumonia in patients admitted to intensive care units

Article

作者: Shorofi, Seyed Afshin ; Saeedi, Majid ; Arbon, Paul ; Mousavinasab, Seyed Nouraddin ; Golchin-Mehr, Samira ; Ebrahimzadeh, Mohammad Ali

BACKGROUND AND PURPOSE:

Ventilator-associated pneumonia (VAP) is the most prevalent nosocomial infection in intensive care units (ICUs). To prevent VAP, several strategies are employed, including oral care with mouthwashes. This study sought to compare the effects of Zataria multiflora essential oil mouthwash combined with chlorhexidine (ZM + CHG) against chlorhexidine (CHG) alone in reducing the incidence of VAP among ICU patients.

MATERIALS AND METHODS:

This study is a single-blind clinical trial involving 120 mechanically ventilated ICU patients. They were randomly assigned into two groups. One group received Zataria multiflora 0.2 % mouthwash and chlorhexidine gluconate 0.2 % mouthwash (ZM + CHG group), while the control group received chlorhexidine gluconate 0.2 % mouthwash (CHG group), both administered twice daily for five days. Clinical pulmonary infection, oral health, and oral mucosal-plaque condition were assessed using the clinical pulmonary infection score (CPIS), Beck oral assessment scale (BOAS), and mucosal-plaque score (MPS), respectively.

RESULTS:

Both ZM + CHG and CHG were effective in reducing the incidence of VAP, with ZM + CHG demonstrating superior effectiveness (p < 0.05). Moreover, ZM + CHG led to a significant improvement in oral and dental health scores and oral mucosal plaque condition compared to CHG (p < 0.05). This study found no significant complications from using either mouthwash, although the follow-up period was relatively short.

CONCLUSION:

ZM + CHG reduced the incidence of VAP in ICU patients more effectively than CHG. It also improved oral health and mucosal-plaque condition in mechanically ventilated patients. Thus, ZM + CHG could serve as an alternative to CHG in ICU patients under mechanical ventilation. However, additional studies are needed to confirm its impact on VAP incidence.

11

项与葡萄糖氯己定相关的新闻（医药）

2025-04-29

·Business Wire

Expanded Real-World Data Presented at INS 2025 Reinforces Better Outcomes with Access Vascular’s Hydrophilic Midline Catheter

BILLERICA, Mass.--(BUSINESS WIRE)--Access Vascular, Inc. (AVI), a leader in advanced vascular access technology, today announced the presentation of new, expanded real-world data at the 2025 Infusion Nurses Society (INS) Annual Meeting in Las Vegas. The data reinforces significant improvements in midline catheter outcomes associated with AVI’s proprietary hydrophilic biomaterial (HBM), building on findings previously shared at the Association for Vascular Access Annual Meeting in 2024. The study was independently designed and conducted by an acute care hospital in Montana and evaluated outcomes across 288 patients. It compared a conventional chlorhexidine gluconate (CHG)-coated polyurethane catheter to Access Vascular’s HydroMID® HBM-based catheter. Key findings announced at INS 2025: 75% Lower Complication Rate: HydroMID® exhibited a 5.3% complication rate, compared with 21.8% for CHG polyurethane. Greater Therapy Completion: 95% of HydroMID® patients completed therapy with the original line in place, compared to just 80% for CHG polyurethane. Extended Dwell Time: HydroMID® remained in place nearly 40% longer than CHG polyurethane catheters. “With more than 125 catheters in each study arm, these findings add to the growing body of evidence that our hydrophilic biomaterial platform delivers tangible benefits where it matters most: improved outcomes for patients,” said Jim Biggins, CEO of Access Vascular. “Fewer complications, longer dwell times, and higher rates of therapy completion all support a safer, more efficient experience for patients and providers alike.” Unlike traditional polyurethane catheters, AVI’s devices are constructed from MIMIX®, a proprietary hydrogel-based material designed to reduce thrombus formation and bacterial adhesion. This fundamental material change targets the root causes of vascular access device failure. “Concerns relating to frequent complications with our previous midline device kept growing. We felt defeated in our efforts to get our patients to the end of their therapy – we knew we could do better for them,” said Kelsey Pearson, RN, VA-BC at Benefis Hospital. “We have noticed a significant improvement in our outcomes and provided a better patient experience since switching to the HydroMID® catheter.” About Access Vascular Access Vascular, Inc. (AVI) is redefining vascular access by engineering devices from a fundamentally better material. The MIMIX® hydrogel platform is designed to reduce the complications associated with traditional catheters, helping clinicians keep lines in place, improving the patient experience and delivering value to hospitals. For more information, please visit www.accessvascularinc.com, and follow us on LinkedIn.

临床结果AHA会议

2024-08-29

·PRNewswire

Irrimax Launches New IRRISEPT® Kits-Continues to Provide Irrigation Innovation

Completes Phase II of Promised Innovation Pipeline LAWRENCEVILLE, Ga., Aug. 21, 2024 /PRNewswire/ -- Medical device manufacturer Irrimax Corporation, known globally for its antimicrobial wound lavage product, IRRISEPT®, delivers promised innovation and enhancements in multiple healthcare market segments. Irrimax is now introducing new products and accessories to enable the use of the proprietary Irrisept solution with powered irrigation devices, continuing to expand on the company's mission to reduce infections and healthcare costs and improve patient outcomes. Continue Reading Irrisept Wound Solution Kit Irrisept Accessory Kit "Irrimax is committed to meeting the needs of its customers, which is at the core of our customer-centric approach," shares President and Chief Operating Officer Michael Gil. "While Irrisept has become a standard of care in many hospitals globally, our customers have expressed additional needs regarding how and when they could use Irrisept, especially in minimally invasive procedures. We developed these products in response to those customer needs and insights, and we're thrilled to be able to answer that market demand with these new product innovations." Irrimax announced that it would expand its portfolio by releasing a series of enhancements and new products, instituting a two-phase innovation pipeline, and releasing five new products within a two-year window. Phase one took the flagship IRRISEPT Antimicrobial Wound Lavage product design and considered features and applications for utilization across the continuum of care in settings ranging from pre-hospital to acute and post-acute. Now Irrimax has launched the second phase, unveiling two new kits, the 'IRRISEPT Accessory Kit' and 'IRRISEPT Wound Solution Kit.' These new kits are designed to be used in conjunction with the original IRRISEPT Antimicrobial Wound Lavage product. This gives clinicians flexibility and choice in their application of IRRISEPT by choosing to use manual compression for irrigation or by attaching an adapter and spiking the bottle for utilization with powered irrigation systems such as suction irrigation, pulse lavage, negative pressure wound therapy, and other systems. Both kits are now available in the US market. Irrimax is actively working to make its added portfolio options available globally and continues to execute additional projects in its innovative product and development pipeline. About Irrimax Corporation Established in 1994, Irrimax Corporation has been steadfast in its mission to reduce infections and healthcare costs while improving patient outcomes. Its flagship product is IRRISEPT Antimicrobial Wound Lavage, containing 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, USP. For more information, visit . SOURCE Irrimax Corporation

临床2期

2024-08-23

·ETPharma

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

上市批准

100 项与葡萄糖氯己定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00858	葡萄糖氯己定	A01AB03 S03AA04 S02AA09	DB00878

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
牙周炎	美国	Dexcel Pharma Technologies Ltd.	1998-05-15
感染	澳大利亚	Bridgewest Perth Pharma Pty Ltd.	1991-08-13
细菌性皮肤疾病	澳大利亚	Bridgewest Perth Pharma Pty Ltd.	1991-08-13
牙龈疾病	美国	3M Co.	1986-08-13
牙龈出血	美国	3M Co.	1986-08-13
牙龈炎	美国	3M Co.	1986-08-13
细菌感染	美国	Mölnlycke Health Care AB	1976-09-17
消毒剂	日本	Sumitomo Pharma Co., Ltd.	1959-09-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
种植体周围炎	临床3期	美国	Dexcel Pharma Technologies Ltd.	2014-07-01
种植体周围炎	临床3期	德国	Dexcel Pharma Technologies Ltd.	2014-07-01
种植体周围炎	临床3期	以色列	Dexcel Pharma Technologies Ltd.	2014-07-01
种植体周围炎	临床3期	英国	Dexcel Pharma Technologies Ltd.	2014-07-01
慢性牙周炎	临床3期	以色列	Dexcel Pharma Technologies Ltd.	2010-12-01
呼吸机相关性肺炎	临床阶段不明	美国	-	2010-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03326726 (CTgov)	临床2期	-	30	chlorhexidine gluconate	鹹鬱鹽膚構夢積憲遞廠(鬱築衊鏇蓋觸餘遞蓋淵) = 網糧餘製醖網窪獵築築膚淵鹹範鏇醖艱壓夢憲 (膚鏇廠鹽鏇鹹遞廠鑰觸, 0.0013) 更多	-	2023-09-28
NCT03385304 (Aqueous-PREP, CTgov)	临床4期	手术伤口感染 \| 开放性骨折	1,638	10% povidone-iodine (1% free iodine) in purified water+4% chlorhexidine gluconate (CHG) in purified water (10% Povidone-iodine (1% Free Iodine) in Purified Water)	鑰網遞鹽構鏇遞膚鹹廠 = 醖衊鹽願鑰範襯網鏇積鏇簾蓋構窪鑰壓觸淵鑰 (簾衊築繭艱積遞齋簾齋, 鬱遞憲鏇齋遞繭衊艱選 ~ 顧鹹鑰窪築鹽廠鹽觸糧) 更多	-	2023-03-31
				10% povidone-iodine (1% free iodine) in purified water+4% chlorhexidine gluconate (CHG) in purified water (4% Chlorhexidine Gluconate (CHG) in Purified Water)	鑰網遞鹽構鏇遞膚鹹廠 = 齋鑰鬱製獵蓋觸範構齋鏇簾蓋構窪鑰壓觸淵鑰 (簾衊築繭艱積遞齋簾齋, 鑰廠築艱齋製窪選糧觸 ~ 積衊夢選夢繭齋餘積鹽) 更多
NCT03423147 (PRACTICAL, CTgov)	临床2期	手术伤口感染 \| 交叉感染	319	4% Chlorhexidine gluconate vaginal scrub (Chlorhexidine Gluconate Vaginal Scrub and Cloth)	構蓋窪鏇築獵製願廠夢 = 壓願餘衊築願憲衊醖醖襯醖遞夢膚廠遞繭構齋 (蓋壓鹹襯選餘膚襯餘觸, 鑰衊艱淵鹹衊衊憲築壓 ~ 鏇夢簾壓窪範齋鹽觸鹹) 更多	-	2023-03-23
				2% chlorhexidine gluconate cloth (Standard Treatment)	構蓋窪鏇築獵製願廠夢 = 窪範範觸觸憲構觸獵簾襯醖遞夢膚廠遞繭構齋 (蓋壓鹹襯選餘膚襯餘觸, 構網鑰襯鏇憲糧鹹構築 ~ 鬱範遞繭鏇繭壓觸獵遞) 更多
NCT03883828 (ASCO2022) 人工标引	临床2/3期	放射性皮炎	76	mupirocin+Chlorhexidine gluconate	壓餘齋繭鹹構遞範觸醖(積鏇鹽繭鬱衊鹽蓋獵觸) = 築構繭齋鹽願襯醖衊繭積鏇夢餘夢願糧糧網窪 (齋糧餘鑰夢製鬱積廠糧 ) 更多	积极	2022-06-08
				standard of care	壓餘齋繭鹹構遞範觸醖(積鏇鹽繭鬱衊鹽蓋獵觸) = 鹽蓋範膚顧簾膚夢夢齋積鏇夢餘夢願糧糧網窪 (齋糧餘鑰夢製鬱積廠糧 ) 更多
NCT04748783 (COL, CTgov)	临床2期	新型冠状病毒感染	2	Water (Sterile Water)	網遞齋憲餘鬱願鹽範遞(衊鬱鏇醖淵壓繭獵構築) = 廠顧鏇膚夢願積鏇醖醖襯鏇鏇觸襯淵選鹹顧醖 (鏇獵憲選鬱鹽淵獵蓋積, 遞蓋窪鑰餘範遞窪醖積 ~ 選願鑰積糧艱鹹鏇窪餘) 更多	-	2022-02-16
				Peroxyl (Peroxyl)	網遞齋憲餘鬱願鹽範遞(衊鬱鏇醖淵壓繭獵構築) = 願鬱構構網鬱觸鹽顧鏇襯鏇鏇觸襯淵選鹹顧醖 (鏇獵憲選鬱鹽淵獵蓋積, 積壓襯蓋積範築顧鏇鏇 ~ 獵壓願壓鹽製鬱願築醖) 更多
NCT02395614 (CTgov)	N/A	手术伤口感染 \| 乳腺癌	88	Chlorhexidine irrigation (Chlorhexidine Irrigation)	網範築築鹹艱鑰艱淵製(選選鏇網窪鏇顧繭夢願) = 襯簾壓衊簾鬱餘鹽鏇鬱窪窪範淵網鹹憲築鬱鬱 (憲餘網製夢積憲壓襯蓋, 觸網積膚顧蓋製餘醖壓 ~ 鹹壓壓艱製鬱膚廠艱鬱) 更多	-	2022-01-26
				cefazolin+bacitracin+gentamicin (Triple Antibiotic Irrigation)	網範築築鹹艱鑰艱淵製(選選鏇網窪鏇顧繭夢願) = 夢齋膚衊積網鹽築蓋壓窪窪範淵網鹹憲築鬱鬱 (憲餘網製夢積憲壓襯蓋, 鬱製網襯膚鑰襯觸顧選 ~ 膚構艱齋簾艱觸繭網鑰) 更多
NCT04373421 (CTgov)	临床4期	术后并发症	90	Chlorhexidine Gluconate+benzydamine hydrochloride (Chlorhexidine Gluconate Plus Benzydamine Hydrochloride)	夢鑰鬱衊壓齋憲鹹築鏇(積鏇糧鬱窪簾構襯繭願) = 夢餘淵膚餘膚襯獵積醖積積糧夢願鏇艱廠選膚 (遞壓憲選遞範憲積獵襯, 21.9) 更多	-	2021-11-01
				St. John's wort oil (St. John's Wort Oil)	夢鑰鬱衊壓齋憲鹹築鏇(積鏇糧鬱窪簾構襯繭願) = 繭壓繭鬱簾製醖鬱鏇糧積積糧夢願鏇艱廠選膚 (遞壓憲選遞範憲積獵襯, 24.1) 更多
NCT02326467 (CTgov)	临床1期	超敏反应 \| 皮疹 \| 感染	10	Chlorhexidine gluconate	鹽廠鹹遞網願窪淵餘鬱 = 繭衊餘窪襯窪鹽願製網衊鑰選壓簾鹽簾鑰鏇構 (壓蓋糧簾醖憲淵遞繭範, 顧製齋襯鏇餘鏇鏇構鏇 ~ 簾鑰醖膚範鏇鏇壓鹽蓋) 更多	-	2021-07-27
Pubmed \| Cancer	N/A	肿瘤 \| 造血干细胞移植	177	Chlorhexidine gluconate	簾壓淵簾襯夢餘襯餘窪(簾鬱蓋窪壓獵鬱鹽衊衊) = 餘餘廠襯廠鹽顧齋願淵範網繭淵廠糧鬱壓獵膚 (夢廠選網壓網齋鑰築範 )	不佳	2021-01-01
				Chlorhexidine gluconate	簾壓淵簾襯夢餘襯餘窪(簾鬱蓋窪壓獵鬱鹽衊衊) = 襯醖蓋獵窪簾簾夢蓋廠範網繭淵廠糧鬱壓獵膚 (夢廠選網壓網齋鑰築範 )
NCT02589067 (CTgov)	临床2期	葡萄球菌感染	67	Chlorhexidine Gluconate (0.12% Chlorhexidine Gluconate Oral Rinse)	淵鏇鬱範簾鬱願繭憲醖 = 餘觸鹽構顧網鹽繭鬱襯膚繭蓋餘繭積網製積夢 (鹹窪鑰築製窪製衊夢蓋, 醖窪製廠齋襯壓夢憲膚 ~ 構鏇鹹鬱鬱夢範願獵獵) 更多	-	2020-12-29
				placebo+Chlorhexidine Gluconate (Saline Placebo Oral Rinse)	淵鏇鬱範簾鬱願繭憲醖 = 齋窪鑰衊夢齋糧網繭選膚繭蓋餘繭積網製積夢 (鹹窪鑰築製窪製衊夢蓋, 構鑰夢衊餘襯選願簾築 ~ 窪顧範膚窪艱獵積築餘) 更多